These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 29946862)

  • 1. Estrogen-receptor status and risk of contralateral breast cancer following DCIS.
    Stout NK; Cronin AM; Uno H; Ozanne EM; Hassett MJ; Frank ES; Greenberg CC; Punglia RS
    Breast Cancer Res Treat; 2018 Oct; 171(3):777-781. PubMed ID: 29946862
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved outcomes of breast-conserving therapy for patients with ductal carcinoma in situ.
    Halasz LM; Sreedhara M; Chen YH; Bellon JR; Punglia RS; Wong JS; Harris JR; Brock JE
    Int J Radiat Oncol Biol Phys; 2012 Mar; 82(4):e581-6. PubMed ID: 22208975
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis.
    Kerlikowske K; Molinaro AM; Gauthier ML; Berman HK; Waldman F; Bennington J; Sanchez H; Jimenez C; Stewart K; Chew K; Ljung BM; Tlsty TD
    J Natl Cancer Inst; 2010 May; 102(9):627-37. PubMed ID: 20427430
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinicopathological Risk Factors for an Invasive Breast Cancer Recurrence after Ductal Carcinoma
    Visser LL; Elshof LE; Schaapveld M; van de Vijver K; Groen EJ; Almekinders MM; Bierman C; van Leeuwen FE; Rutgers EJ; Schmidt MK; Lips EH; Wesseling J
    Clin Cancer Res; 2018 Aug; 24(15):3593-3601. PubMed ID: 29685879
    [No Abstract]   [Full Text] [Related]  

  • 5. Expression of HER2neu in ductal carcinoma in situ is associated with local recurrence.
    Han K; Nofech-Mozes S; Narod S; Hanna W; Vesprini D; Saskin R; Taylor C; Kong I; Paszat L; Rakovitch E
    Clin Oncol (R Coll Radiol); 2012 Apr; 24(3):183-9. PubMed ID: 21958729
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP protocol B-24.
    Allred DC; Anderson SJ; Paik S; Wickerham DL; Nagtegaal ID; Swain SM; Mamounas EP; Julian TB; Geyer CE; Costantino JP; Land SR; Wolmark N
    J Clin Oncol; 2012 Apr; 30(12):1268-73. PubMed ID: 22393101
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tamoxifen Initiation After Ductal Carcinoma In Situ.
    Nichols HB; Bowles EJ; Islam J; Madziwa L; Stürmer T; Tran DT; Buist DS
    Oncologist; 2016 Feb; 21(2):134-40. PubMed ID: 26768485
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical risk score to predict likelihood of recurrence after ductal carcinoma in situ treated with breast-conserving surgery.
    Punglia RS; Jiang W; Lipsitz SR; Hughes ME; Schnitt SJ; Hassett MJ; Nekhlyudov L; Achacoso N; Edge S; Javid SH; Niland JC; Theriault RL; Wong YN; Habel LA
    Breast Cancer Res Treat; 2018 Feb; 167(3):751-759. PubMed ID: 29079937
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factors Influencing Use of Hormone Therapy for Ductal Carcinoma In Situ: A National Cancer Database Study.
    Nguyen TT; Hoskin TL; Day CN; Habermann EB; Goetz MP; Boughey JC
    Ann Surg Oncol; 2017 Oct; 24(10):2989-2998. PubMed ID: 28766214
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Benefit of low-dose tamoxifen in a large observational cohort of high risk ER positive breast DCIS.
    Guerrieri-Gonzaga A; Sestak I; Lazzeroni M; Serrano D; Rotmensz N; Cazzaniga M; Varricchio C; Pruneri G; Leonardi MC; Orecchia R; Galimberti V; Bonanni B; DeCensi A
    Int J Cancer; 2016 Nov; 139(9):2127-34. PubMed ID: 27381855
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histological type and marker expression of the primary tumour compared with its local recurrence after breast-conserving therapy for ductal carcinoma in situ.
    Bijker N; Peterse JL; Duchateau L; Robanus-Maandag EC; Bosch CA; Duval C; Pilotti S; van de Vijver MJ
    Br J Cancer; 2001 Feb; 84(4):539-44. PubMed ID: 11207051
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characteristics of second breast events among women treated with breast-conserving surgery for DCIS in the community.
    Hassett MJ; Jiang W; Habel LA; Nekhlyudov L; Achacoso N; Acton L; Schnitt SJ; Schrag D; Punglia RS
    Breast Cancer Res Treat; 2016 Feb; 155(3):541-9. PubMed ID: 26843057
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clonal alteration of breast cancer receptors between primary ductal carcinoma in situ (DCIS) and corresponding local events.
    Karlsson E; Sandelin K; Appelgren J; Zhou W; Jirström K; Bergh J; Wärnberg F
    Eur J Cancer; 2014 Feb; 50(3):517-24. PubMed ID: 24275214
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Including the Ductal Carcinoma-In-Situ (DCIS) Score in the Development of a Multivariable Prediction Model for Recurrence After Excision of DCIS.
    Paszat L; Sutradhar R; Zhou L; Nofech-Mozes S; Rakovitch E
    Clin Breast Cancer; 2019 Feb; 19(1):35-46. PubMed ID: 30190195
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression profiling of in vivo ductal carcinoma in situ progression models identified B cell lymphoma-9 as a molecular driver of breast cancer invasion.
    Elsarraj HS; Hong Y; Valdez KE; Michaels W; Hook M; Smith WP; Chien J; Herschkowitz JI; Troester MA; Beck M; Inciardi M; Gatewood J; May L; Cusick T; McGinness M; Ricci L; Fan F; Tawfik O; Marks JR; Knapp JR; Yeh HW; Thomas P; Carrasco DR; Fields TA; Godwin AK; Behbod F
    Breast Cancer Res; 2015 Sep; 17():128. PubMed ID: 26384318
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathologic characteristics of second breast cancers after breast conservation for ductal carcinoma in situ.
    Arvold ND; Punglia RS; Hughes ME; Jiang W; Edge SB; Javid SH; Laronga C; Niland JC; Theriault RL; Weeks JC; Wong YN; Lee SJ; Hassett MJ
    Cancer; 2012 Dec; 118(24):6022-30. PubMed ID: 22674478
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Contralateral Breast Cancer Risk in Women with Ductal Carcinoma In Situ: Is it High Enough to Justify Bilateral Mastectomy?
    Miller ME; Muhsen S; Olcese C; Patil S; Morrow M; Van Zee KJ
    Ann Surg Oncol; 2017 Oct; 24(10):2889-2897. PubMed ID: 28766208
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is there a low-grade precursor pathway in breast cancer?
    King TA; Sakr RA; Muhsen S; Andrade VP; Giri D; Van Zee KJ; Morrow M
    Ann Surg Oncol; 2012 Apr; 19(4):1115-21. PubMed ID: 21935747
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endocrine Therapy Initiation and Medical Oncologist Utilization Among Women Diagnosed with Ductal Carcinoma in Situ.
    Anderson C; Meyer AM; Wheeler SB; Zhou L; Reeder-Hayes KE; Nichols HB
    Oncologist; 2017 May; 22(5):535-541. PubMed ID: 28408621
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HER2-Overexpressing Ductal Carcinoma
    O'Keefe TJ; Blair SL; Hosseini A; Harismendy O; Wallace AM
    Cancer Prev Res (Phila); 2020 Sep; 13(9):761-772. PubMed ID: 32493703
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.